Biohaven Pharmaceutical Holding (BHVN) PT Raised to $165 at Cowen

Cowen analyst Ken Cacciatore raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $165.00 (from $140.00) while maintaining a Outperform rating.

The analyst commented, "Nurtec Q3 revenues have reached $136MM (+46% Q/Q), nicely above the Street's $110MM, and importantly, the net value per Rx continues to strengthen, now at $455 (+5% Q/Q), which nicely complemented the likely prevention-driven inflecting Rx growth. Nurtec continues to validate our views of the product's likely ultimate size and we believe investors need to begin to contemplate the ex-US value. Add."

You May Also Be Interested In

• Biohaven Pharma (BHVN) PT Raised to $23 at RBC Capital
• Jefferies Downgrades Computershare Limited (CPU:AU) (CMSQY) to Hold
• Rapid7 (RPD) PT Raised to $14 at Canaccord